Multi-scale genomic, transcriptomic and proteomic analysis of colorectal cancer cell lines to identify novel biomarkers

PLoS ONE

Volumn 10, Issue 12, 2015, Pages

  Briffa, Romina ^a   Um, Inhwa ^b   Faratian, Dana ^a   Zhou, Ying ^a   Turnbull, Arran K ^a   Langdon, Simon P ^a   Harrison, David J ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF ST ANDREWS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA2 PROTEIN; CASPASE 3; DACTOLISIB; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; FRAGILE HISTIDINE TRIAD PROTEIN; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; OXALIPLATIN; PROTEIN KINASE B; SMOOTHENED PROTEIN; TUMOR MARKER; WNT PROTEIN; ANTINEOPLASTIC AGENT; GENETIC MARKER;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL CYCLE; COHORT ANALYSIS; COLORECTAL CANCER CELL LINE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; COPY NUMBER VARIATION; EGFR GENE; FHIT GENE; FLUORESCENCE IN SITU HYBRIDIZATION; FZD1 GENE; GENE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MUTATION; GENOMICS; HUMAN; HUMAN CELL; IC50; INTRACELLULAR SIGNALING; MACROD2 GENE; MAJOR CLINICAL STUDY; MUTATIONAL ANALYSIS; ONCOGENE K RAS; ONCOGENE MYC; PIK3CA GENE; PROTEIN EXPRESSION; PROTEIN MICROARRAY; PROTEOMICS; SEQUENCE ANALYSIS; SMO GENE; TRANSCRIPTOMICS; TRIB1 GENE; TUMOR SUPPRESSOR GENE; CHEMISTRY; COLORECTAL NEOPLASMS; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETICS; HIGH THROUGHPUT SEQUENCING; TUMOR CELL LINE; TUMOR GENE;

ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GENETIC MARKERS; GENOMICS; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; PROTEOMICS;

EID: 84956646500     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0144708     Document Type: Article

References (102)

1. Ferlay J SH, Bray F, Forman D, Mathers C, Parkin DM. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer; 2010; Available: Http://globocan.iarc.fr/factsheets/cancers/colorectal.asp.
2. American Cancer Society. Global Cancer Facts & Figures 2nd Edition. Atlanta: American Cancer Society; 2011. Available: Http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-027766.pdf
3. Li W, Wang R, Yan Z, Bai L, Sun Z. High accordance in prognosis prediction of colorectal cancer across independent datasets by multi-gene module expression profiles. PLoS ONE. 2012; 7(3): E33653. doi: 10.1371/journal.pone.0033653 PMID: 22438977
4. Colussi D, Brandi G, Bazzoli F, Ricciardiello L. Molecular pathways involved in colorectal cancer: Implications for disease behavior and prevention. Int J Mol Sci. 2013; 14 (8): 16365-85. doi: 10.3390/ijms140816365 PMID: 23965959
5. Bertrand FE, Angus CW, Partis WJ, Sigounas G. Developmental pathways in colon cancer: Crosstalk between WNT, BMP, Hedgehog and Notch. Cell Cycle. 2012; 11 (23): 4344-51. doi: 10.4161/cc. 22134 PMID: 23032367
6. Wood LD, Parsons DW, Jones S, Lin J, Sjoblom T, Leary RJ, et al. The genomic landscapes of human breast and colorectal cancers. Science. 2007; 318 (5853): 1108-13. PMID: 17932254
7. Goel A. Frequent Inactivation of PTEN by Promoter Hypermethylation in Microsatellite Instability-High Sporadic Colorectal Cancers. Cancer Res. 2004; 64 (9): 3014-21. PMID: 15126336
8. Smith G, Carey FA, Beattie J, Wilkie MJ, Lightfoot TJ, Coxhead J, et al. Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A. 2002; 99 (14): 9433-8. PMID: 12093899
9. Fearon ER. Molecular genetics of colorectal cancer. Ann Rev Pathol. 2011; 6: 479-507.
10. Naccarati A, Polakova V, Pardini B, Vodickova L, Hemminki K, Kumar R, et al. Mutations and polymorphisms in TP53 gene-an overview on the role in colorectal cancer. Mutagenesis. 2012; 27 (2): 211-8. doi: 10.1093/mutage/ger067 PMID: 22294769
11. Custodio A, Feliu J. Prognostic and predictive biomarkers for epidermal growth factor receptor-targeted therapy in colorectal cancer: Beyond KRAS mutations. Crit Rev Oncol Hematol. 2013; 85 (1); 45-81. doi: 10.1016/j.critrevonc.2012.05.001 PMID: 22647972
12. Samuels Y, Velculescu VE. Oncogenic mutations of PIK3CA in human cancers. Cell Cycle. 2004; 3 (10): 1221-4. PMID: 15467468
13. NCCN. Clinical practice guidelines in oncology: Colon cancer. 2013. Available: Http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
14. Chu E. An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin Colorectal Cancer. 2012; 11 (1): 1-13. doi: 10.1016/j.clcc.2011.05.005 PMID: 21752724
15. Baselga J. Why the epidermal growth factor receptor? The rationale for cancer therapy. The Oncologist. 2002; 7(Supp 4): 2-8.
16. Weidlich S, Walsh K, Crowther D, Burczynski ME, Feuerstein G, Carey FA, et al. Pyrosequencingbased methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours. Brit J Cancer. 2011; 105 (2): 246-54. doi: 10.1038/bjc.2011.197 PMID: 21712828
17. Scartozzi M, Bearzi I, Mandolesi A, Giampieri R, Faloppi L, Galizia E, et al. Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. Brit J Cancer. 2011; 104 (11): 1786-90. doi: 10.1038/bjc.2011.161 PMID: 21559018
18. Bunz F, Dutriaux A, Lengauer C, Waldman T, Zhou S, Brown JP, et al. Requirement for p53 and p21 to Sustain G2 Arrest After DNA Damage. Science 1998; 282 (5393): 1497-1501. PMID: 9822382
19. Barnetson RA, Tenesa A, Farrington SM, Nicholl ID, Cetnarskyj R, Porteous ME, et al. Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. N Engl J Med 2006; 354 (26): 2751-63. PMID: 16807412
20. Faratian D, Goltsov A, Lebedeva G, Sorokin A, Moodie S, Mullen P, et al. Systems biology reveals new strategies for personalizing cancer medicine and confirms the role of PTEN in resistance to trastuzumab. Cancer Res. 2009; 69 (16): 6713-20. doi: 10.1158/0008-5472.CAN-09-0777 PMID: 19638581
21. Spurrier B, Ramalingam S, Nishizuka S. Reverse-phase protein lysate microarrays for cell signaling analysis. Nat Protoc. 2008; 3 (11): 1796-808. doi: 10.1038/nprot.2008.179 PMID: 18974738
22. Meyer C, Sims AH, Morgan K, Harrison B, Muir M, Bai J, et al. Transcript and protein profiling identify signaling, growth arrest, apoptosis and NF?B-survival signatures following GnRH receptor activation. Endocr Relat Cancer. 2013; 20 (1): 123-136. doi: 10.1530/ERC-12-0192 PMID: 23202794
23. Glaab E, Garibaldi JM, Krasnogor N. ArrayMining: A modular web-application for microarray analysis combining ensemble and consensus methods with cross-study normalization. BMC Bioinformatics. 2009; 10: 358. doi: 10.1186/1471-2105-10-358 PMID: 19863798
24. Huang da W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009; 4 (1): 44-57. doi: 10.1038/nprot.2008.211 PMID: 19131956
25. De Hoon MJ, Imoto S, Nolan J, Miyano S. Open source clustering software. Bioinformatics. [Comparative StudyEvaluation StudiesValidation Studies]. 2004; 20 (9): 1453-4. PMID: 14871861
26. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, et al. TM4: A free, open-source system for microarray data management and analysis. Bioechniques. 2003; 34 (2): 374-8.
27. Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998; 4 (7): 844-7. PMID: 9662379
28. Faratian D, Christiansen J, Gustavson M, Jones C, Scott C, Um I, et al. Heterogeneity mapping of protein expression in tumors using quantitative immunofluorescence. J Vis Exp. 2011: E3334. doi: 10. 3791/3334 PMID: 22064683
29. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst. 2005; 97 (24): 1808-15. PMID: 16368942
30. Varella-Garcia M, Diebold J, Eberhard DA, Geenen K, Hirschmann A, Kockx M, et al. EGFR fluorescence in situ hybridisation assay: Guidelines for application to non-small-cell lung cancer. J Clin Pathol. 2009; 62 (11): 970-7. doi: 10.1136/jcp.2009.066548 PMID: 19861557
31. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007; 25 (1): 118-45. PMID: 17159189
32. Knutsen T, Padilla-Nash HM, Wangsa D, Barenboim-Stapleton L, Camps J, McNeil N, et al. Definitive molecular cytogenetic characterization of 15 colorectal cancer cell lines. Genes, chromosomes & cancer. 2010; 49 (3): 204-23.
33. Bracht K, Nicholls AM, Liu Y, Bodmer WF. 5-Fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.Br J Cancer. 2010; 103 (3):340-6. doi: 10. 1038/sj.bjc.6605780 PMID: 20606684
34. Longley DB, Johnston PG. 5-Fluorouracil: Apoptosis, Cell Signaling, and Human Diseases. In: Srivastava R, editor.: Humana Press; 2007. p. 263-278.
35. Mariadason JM, Arango D, Shi Q, Wilson AJ, Corner GA, Nicholas C, et al. Gene expression profilingbased prediction of response of colon carcinoma cells to 5-fluorouracil and camptothecin. Cancer Res. 2003; 63 (24): 8791-812. PMID: 14695196
36. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehmé A, et al. The Role of DNA Mismatch Repair in Platinum Drug Resistance. Cancer Res. 1996; 56 (21): 4881-6. PMID: 8895738
37. Boyer J, McLean EG, Aroori S, Wilson P, McCulla A, Carey PD, et al. Characterization of p53 Wild-Type and Null Isogenic Colorectal Cancer Cell Lines Resistant to 5-Fluorouracil, Oxaliplatin, and Irinotecan. Clin Cancer Res. 2004; 10 (6): 2158-67. PMID: 15041737
38. Pietrantonio F, Biondani P, Perrone F, Di Bartolomeo M, Pacifici M, Milione M, et al. TP53 mutations in advanced colorectal cancer: The dark side of the moon. Oncology. 2014; 86 (5-6): 89-294.
39. Serra V, Markman B, Scaltriti M, Eichhorn PJ, Valero V, Guzman M, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations. Cancer Res. 2008; 68 (19): 8022-30. doi: 10.1158/0008-5472.CAN-08-1385 PMID: 18829560
40. Jones AM, Douglas EJ, Halford SE, Fiegler H, Gorman PA, Roylance RR, et al. Array-CGH analysis of microsatellite-stable, near-diploid bowel cancers and comparison with other types of colorectal carcinoma. Oncogene. 2005; 6; 24 (1): 118-29. PMID: 15531920
41. Camps J, Nguyen QT, Padilla-Nash HM, Knutsen T, McNeil NE, Wangsa D, et al. Integrative genomics reveals mechanisms of copy number alterations responsible for transcriptional deregulation in colorectal cancer. Genes, chromosomes & cancer. 2009; 48 (11): 1002-17.
42. Xie T, DA G, Lamb JR, Martin E, Wang K, Tejpar S, et al. A comprehensive characterization of genome-wide copy number aberrations in colorectal cancer reveals novel oncogenes and patterns of alterations. PLoS ONE. 2012; 7 (7): E42001. doi: 10.1371/journal.pone.0042001 PMID: 22860045
43. Shi Z-Z, Zhang Y-M, Shang L, Hao J-J, Zhang T-T, Wang B-S, et al. Genomic profiling of rectal adenoma and carcinoma by array-based comparative genomic hybridization. BMC Medical Genomics. 2012; 5 (1): 52.
44. Loo LW, Tiirikainen M, Cheng I, Lum-Jones A, Seifried A, Church JM, et al. Integrated analysis of genome-wide copy number alterations and gene expression in microsatellite stable, CpG island methylator phenotype-negative colon cancer. Genes, Chromosomes & Cancer. 2013; 52 (5): 450-66.
45. Arnold CN, Goel A, Boland CR. Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. Int J Cancer. 2003; 10; 106 (1): 66-73. PMID: 12794758
46. Rochette PJ, Bastien N, McKay BC, Therrien JP, Drobetsky EA, Drouin R. Human cells bearing homozygous mutations in the DNA mismatch repair genes hMLH1 or hMSH2 are fully proficient in transcription-coupled nucleotide excision repair. Oncogene. 2002; 21 (37): 5743-52. PMID: 12173044
47. Williams JR, Zhang Y, Zhou H, Gridley DS, Koch CJ, Dicello JF, et al. Tumor response to radiotherapy is dependent on genotype-associated mechanisms in vitro and in vivo. Radiat Oncol. 2010; 5 71 doi: 10.1186/1748-717X-5-71 PMID: 20704711
48. Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 2010; 29 (14): 2013-23. doi: 10.1038/onc.2009.489 PMID: 20101236
49. Mackay A, Tamber N, Fenwick K, Iravani M, Grigoriadis A, Dexter T, et al. A high-resolution integrated analysis of genetic and expression profiles of breast cancer cell lines. Breast Cancer Res Treat. 2009; 118 (3): 481-98. doi: 10.1007/s10549-008-0296-7 PMID: 19169812
50. Bhushan L, Kandpal RP. EphB6 receptor modulates micro RNA profile of breast carcinoma cells. PLoS ONE. 2011; 6 (7): E22484. doi: 10.1371/journal.pone.0022484 PMID: 21811619
51. Ghoussaini M, Song H, Koessler T, Al Olama AA, Kote-Jarai Z, Driver KE, et al. Multiple loci with different cancer specificities within the 8q24 gene desert. J Natl Cancer Inst. 2008; 100:962-6. doi: 10. 1093/jnci/djn190 PMID: 18577746
52. Yokoyama T, Nakamura T. Tribbles in disease: Signaling pathways important for cellular function and neoplastic transformation. Cancer Sci. 2011; 102 (6): 1115-22. doi: 10.1111/j.1349-7006.2011. 01914.x PMID: 21338441
53. Drosten M, Dhawahir A, Sum EY, Urosevic J, Lechuga CG, Esteban LM, et al. Genetic analysis of Ras signalling pathways in cell proliferation, migration and survival. Embo J. 2010; 29:1091-104. doi: 10.1038/emboj.2010.7 PMID: 20150892
54. Kolch W. Meaningful relationships: The regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J. 2000; 351:289-305. PMID: 11023813
55. Cagnol S, Chambard JC. ERK and cell death: Mechanisms of ERK-induced cell death-apoptosis, autophagy and senescence. Febs J. 2010; 277:2-21. doi: 10.1111/j.1742-4658.2009.07366.x PMID: 19843174
56. Fritsche-Guenther R, Witzel F, Sieber A, Herr R, Schmidt N, Braun S, et al. Strong negative feedback from Erk to Raf confers robustness to MAPK signalling. Molecular systems biology. 2011; 7:489. doi: 10.1038/msb.2011.27 PMID: 21613978
57. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, et al. Oncomine 3.0: Genes, Pathways, and Networks in a Collection of 18,000 Cancer Gene Expression Profiles. Neoplasia. 2007; 9 (2): 166-80. PMID: 17356713
58. Weinstein M, Yang X, Li C, Xu X, Gotay J, Deng CX. Failure of egg cylinder elongation and mesoderm induction in mouse embryos lacking the tumor suppressor smad2. Proc Natl Acad Sci U S A. 1998; 95 (16): 9378-83. PMID: 9689088
59. Mady HH, Melhem MF. FHIT protein expression and its relation to apoptosis, tumor histologic grade and prognosis in colorectal adenocarcinoma: An immunohistochemical and image analysis study. Clin Exp Metastasis. 2002; 19 (4): 351-8. PMID: 12090476
60. Lassmann S, Weis R, Makowiec F, Roth J, Danciu M, Hopt U, et al. Array CGH identifies distinct DNA copy number profiles of oncogenes and tumor suppressor genes in chromosomal-and microsatelliteunstable sporadic colorectal carcinomas. J Mol Med. 2007; 85 (3): 293-304. PMID: 17143621
61. Reed JC. Double identity for proteins of the Bcl-2 family. Nature. 1997; 387 (6635): 773-6. PMID: 9194558
62. Linnebacher M, Ostwald C, Koczan D, Salem T, Schneider B, Krohn M, et al. Single nucleotide polymorphism array analysis of microsatellite-stable, diploid/near-diploid colorectal carcinomas without the CpG island methylator phenotype. Oncol Lett. 2013; 5 (1): 173-8. PMID: 23255915
63. La Cour JM, Mollerup J, Winding P, Tarabykina S, Sehested M, Berchtold MW. Up-regulation of ALG-2 in hepatomas and lung cancer tissue. Am J Pathol. 2003; 163 (1): 81-9. PMID: 12819013
64. Su D, Xu H, Feng J, Gao Y, Gu L, Ying L, et al. PDCD6 is an independent predictor of progression free survival in epithelial ovarian cancer. J Transl Med. 2012; 10 31 doi: 10.1186/1479-5876-10-31 PMID: 22369209
65. Suzuki K, Dashzeveg N, Lu ZG, Taira N, Miki Y, Yoshida K. Programmed cell death 6, a novel p53-responsive gene, targets to the nucleus in the apoptotic response to DNA damage. Cancer science. 2012; 103 (10): 1788-94. doi: 10.1111/j.1349-7006.2012.02362.x PMID: 22712728
66. Rho SB, Song YJ, Lim MC, Lee S-H, Kim B-R, Park S-Y. Programmed cell death 6 (PDCD6) inhibits angiogenesis through PI3K/mTOR/p70S6K pathway by interacting of VEGFR-2. Cellular Signalling. 2012; 24 (1): 131-9. doi: 10.1016/j.cellsig.2011.08.013 PMID: 21893193
67. Park SH, Lee JH, Lee G-B, Byun H-J, Kim B-R, Park C-Y, et al. PDCD6 additively cooperates with anti-cancer drugs through activation of NF-?B pathways. Cellular Signalling. 2012; 24 (3): 726-33. doi: 10.1016/j.cellsig.2011.11.006 PMID: 22142513
68. Edwards MC, Liegeois N, Horecka J, DePinho RA, Sprague GF Jr., Tyers M, et al. Human CPR (cell cycle progression restoration) genes impart a Far-phenotype on yeast cells. Genetics. 1997; 147 (3): 1063-76. PMID: 9383053
69. da Silva Correia J, Miranda Y, Leonard N, Hsu J, Ulevitch RJ. Regulation of Nod1-mediated signaling pathways. Cell death and differentiation. 2007; 14 (4): 830-9. PMID: 17186025
70. Tsafrir D, Bacolod M, Selvanayagam Z, Tsafrir I, Shia J, Zeng Z, et al. Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res. 2006; 66 (4): 2129-37. PMID: 16489013
71. Brough R, Bajrami I, Vatcheva R, Natrajan R, Reis-Filho JS, Lord CJ, et al. APRIN is a cell cycle specific BRCA2-interacting protein required for genome integrity and a predictor of outcome after chemotherapy in breast cancer. Embo J. 2012; 31 (5): 1160-76. doi: 10.1038/emboj.2011.490 PMID: 22293751
72. Lockwood WW, Thu KL, Lin L, Pikor LA, Chari R, Lam WL, et al. Integrative genomics identified RFC3 as an amplified candidate oncogene in esophageal adenocarcinoma. Clin Cancer Res. 2012; 18 (7): 1936-46. doi: 10.1158/1078-0432.CCR-11-1431 PMID: 22328562
73. Mojica W, Hawthorn L. Normal colon epithelium: A dataset for the analysis of gene expression and alternative splicing events in colon disease. BMC Genomics. 2010; 11: 5. doi: 10.1186/1471-2164-11-5 PMID: 20047688
74. Ellison V, Stillman B. Reconstitution of recombinant human replication factor C (RFC) and identification of an RFC subcomplex possessing DNA-dependent ATPase activity. J Biol Chem. 1998; 273 (10): 5979-87. PMID: 9488738
75. Huppi K, Pitt JJ, Wahlberg BM, Caplen NJ. The 8q24 gene desert: An oasis of non-coding transcriptional activity. Frontiers in Genetics. 2012; 3 69 doi: 10.3389/fgene.2012.00069 PMID: 22558003
76. Peng X, Cao P, Li J, He D, Han S, Zhou J, et al. MiR-1204 sensitizes nasopharyngeal carcinoma cells to paclitaxel both in vitro and in vivo. Cancer Biol Ther. 2015; 16 (2): 261-7. doi: 10.1080/15384047. 2014.1001287 PMID: 25756509
77. Barsotti AM, Beckerman R, Laptenko O, Huppi K, Caplen NJ, Prives C. p53-dependent Induction of PVT1 and miR-1204. J Biol Chem. 2011; 287 (4): 2509-19. doi: 10.1074/jbc.M111.322875 PMID: 22110125
78. Kim H, Kang K, Kim J. AEBP2 as a potential targeting protein for Polycomb Repression Complex PRC2. Nucleic Acids Res. 2009; 37 (9): 2940-50. doi: 10.1093/nar/gkp149 PMID: 19293275
79. Huang L, Zheng M, Zhou QM, Zhang MY, Yu YH, Yun JP, et al. Identification of a 7-gene signature that predicts relapse and survival for early stage patients with cervical carcinoma. Med Oncol. 2012; 29 (4): 2911-8. doi: 10.1007/s12032-012-0166-3 PMID: 22274917
80. Kurisaki A, Kurisaki K, Kowanetz M, Sugino H, Yoneda Y, Heldin CH, et al. The mechanism of nuclear export of Smad3 involves exportin 4 and Ran. Mol Cell Biol. 2006; 26 (4):1318-32. PMID: 16449645
81. Tan J, Yu Q. Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy. Chinese journal of cancer. 2013; 32 (7): 376-9. doi: 10.5732/cjc.012.10287 PMID: 23668928
82. Ilic N, Utermark T, Widlund HR, Roberts TM. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proceedings of the National Academy of Sciences of the United States of America. 2011; 108 (37): E699-708. doi: 10.1073/pnas. 1108237108 PMID: 21876152
83. Lagerstedt KK, Kristiansson E, Lönnroth C, Andersson M, Iresjö B-M, Gustafsson A, et al. Genes with Relevance for Early to Late Progression of Colon Carcinoma Based on Combined Genomic and Transcriptomic Information from the Same Patients. Cancer Informatics. 2010; 9: 79-91. PMID: 20467480
84. Cervigne NK, Machado J, Goswami RS, Sadikovic B, Bradley G, Perez-Ordonez B, et al. Recurrent genomic alterations in sequential progressive leukoplakia and oral cancer: Drivers of oral tumorigenesis? Hum mol genetics. 2014; 23 (10): 2618-28.
85. Jung JJ, Jeung HC, Lee JO, Kim TS, Chung HC, Rha SY. Putative chemosensitivity predictive genes in colorectal cancer cell lines for anticancer agents. Oncol Rep. 2007; 18 (3): 593-9. PMID: 17671706
86. Zhang C, Elkahloun AG, Robertson M, Gills JJ, Tsurutani J, Shih JH, et al. Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance. PLoS ONE. 2011; 6 (8): E23849. doi: 10.1371/journal.pone.0023849 PMID: 21887332
87. Yao Y, Jia X-Y, Tian H-Y, Jiang Y-X, Xu G-J, Qian Q-J, et al. Comparative proteomic analysis of colon cancer cells in response to Oxaliplatin treatment. Biochimica et Biophysica Acta (BBA)-Proteins and Proteomics. 2009; 1794 (10): 1433-40.
88. Goga A, Yang D, Tward AD, Morgan DO, Bishop JM. Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC.Nature medicine.2007; 13 (7):820-7. PMID: 17589519
89. Yang D, Liu H, Goga A, Kim S, Yuneva M, Bishop JM. Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase. Proc Nat Acad Sci USA. 2010; 107 (31): 13836-4841. doi: 10.1073/pnas.1008366107 PMID: 20643922
90. Moser R, Toyoshima M, Robinson K, Gurley KE, Howie HL, Davison J, et al. MYC-driven tumorigenesis is inhibited by WRN syndrome gene deficiency. Mol Cancer Res. 2012; 10 (4): 535-45. doi: 10. 1158/1541-7786.MCR-11-0508 PMID: 22301954
91. Toyoshima M, Howie HL, Imakura M, Walsh RM, Annis JE, Chang AN, et al. Functional genomics identifies therapeutic targets for MYC-driven cancer. Proc Nat Acad Sci USA. 2012; 109 (24): 9545-50. doi: 10.1073/pnas.1121119109 PMID: 22623531
92. Shortt J, Johnstone RW. Oncogenes in cell survival and cell death. Cold Spring Harb Perspect Biol. 2012; 4: (12).
93. Kiss-Toth E, Bagstaff SM, Sung HY, Jozsa V, Dempsey C, Caunt JC, et al. Human tribbles, a protein family controlling mitogen-activated protein kinase cascades. J Biol Chem. 2004; 279 (41): 42703-8. PMID: 15299019
94. Du K, Herzig S, Kulkarni RN, Montminy M. TRB3: A tribbles homolog that inhibits Akt/PKB activation by insulin in liver. Science.2003; 300 (5625): 1574-7. PMID: 12791994
95. Vogel C, Marcotte EM. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat Rev Genet. 2012; 13 (4): 227-32. doi: 10.1038/nrg3185 PMID: 22411467
96. Sharova LV, Sharov AA, Nedorezov T, Piao Y, Shaik N, Ko MS. Database for mRNA half-life of 19 977 genes obtained by DNA microarray analysis of pluripotent and differentiating mouse embryonic stem cells. DNA Res. 2009; 16 (1):45-58. doi: 10.1093/dnares/dsn030 PMID: 19001483
97. Schwanhausser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, et al. Global quantification of mammalian gene expression control. Nature. 2011; 473 (7347): 337-42. doi: 10.1038/nature10098 PMID: 21593866
98. Raghavan A, Bohjanen PR. Microarray-based analyses of mRNA decay in the regulation of mammalian gene expression. Brief Funct Genomic Proteomic. 2004 3 (2):112-24. PMID: 15355594
99. Wang H, Huang S, Shou J, Su EW, Onyia JE, Liao B, et al. Comparative analysis and integrative classification of NCI60 cell lines and primary tumors using gene expression profiling data. BMC Genomics. 2006; 7: 166 PMID: 16817967
100. Spitzner M, Emons G, Kramer F, Gaedcke J, Rave-Frank M, Scharf JG, et al. A gene expression signature for chemoradiosensitivity of colorectal cancer cells. International journal of radiation oncology, biology, physics. 2010; 78 (4): 1184-92. doi: 10.1016/j.ijrobp.2010.06.023 PMID: 20970032
101. Heiser LM, Sadanandam A, Kuo WL, Benz SC, Goldstein TC, Ng S, et al. Subtype and pathway specific responses to anticancer compounds in breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109 (8): 2724-9. doi: 10.1073/pnas.1018854108 PMID: 22003129
102. Sadanandam A, Lyssiotis CA, Homicsko K, Collisson EA, Gibb WH, Wullschleger S, et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nature Medicine.2013; 19; 619-25. doi: 10.1038/nm.3175 PMID: 23584089